These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19947374)

  • 21. Treatment of prostate cancer with hormonal therapy in Europe.
    Miller K; Anderson J; Abrahamsson PA
    BJU Int; 2009 Mar; 103 Suppl 2():2-6. PubMed ID: 19228146
    [No Abstract]   [Full Text] [Related]  

  • 22. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
    Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
    Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary combined androgen blockade in localized disease and its mechanism.
    Namiki M; Kitagawa Y; Mizokami A; Koh E
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):303-15. PubMed ID: 18471788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
    Odrazka K; Vaculikova M; Dolezel M; Petera J; Moravek P; Prosvic P; Zoul Z; Vosmik M; Dolezal J; Simakova E
    Oncol Rep; 2005 Oct; 14(4):1077-81. PubMed ID: 16142375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways.
    Pitts WR
    BJU Int; 2009 Nov; 104(9):1304. PubMed ID: 19824968
    [No Abstract]   [Full Text] [Related]  

  • 28. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of somatostatin analogs in the management of prostate cancer.
    Sinisi AA; Rossi V; Prezioso D; Notaro A; Bellastella G; Panza N; Bellastella A; Pasquali D
    J Endocrinol Invest; 2003; 26(8 Suppl):120-4. PubMed ID: 15233227
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemotherapy for localized, high-risk prostate cancer.
    Narayan S; Smith DC; Sandler HM
    Semin Radiat Oncol; 2003 Apr; 13(2):152-7. PubMed ID: 12728444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 32. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of chemotherapy in prostate cancer. Minireview.
    Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S
    Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer--treatment of disseminated disease.
    Abi-Aad AS; Opsomer RJ
    Acta Urol Belg; 1996 May; 64(2):67-76. PubMed ID: 8701817
    [No Abstract]   [Full Text] [Related]  

  • 36. Prostate cancer chemotherapy: emerging from the shadows.
    Roth BJ
    J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
    [No Abstract]   [Full Text] [Related]  

  • 37. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of androgen receptor protein in hormone refractory prostate cancer].
    Zhang Y; Chen W; Hu XK; Gui ZN
    Ai Zheng; 2003 Jan; 22(1):95-7. PubMed ID: 12561446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
    Têtu B
    Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.